α1-Antitrypsin Augmentation Therapy for PI*MZ Heterozygotes
Authors:
- Robert A. SandhausRSRobert A. Sandhaus
- Gerard TurinoGTGerard Turino
- Charlie StrangeCSCharlie Strange
- James K. StollerJSJames K. Stoller
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Delay in Diagnosis of α1-Antitrypsin DeficiencyChest, 2005
- Trends in the Diagnosis of Symptomatic Patients With α 1 -Antitrypsin Deficiency Between 1968 and 2003Chest, 2005
- Chronic obstructive pulmonary disease in 1-antitrypsin PI MZ heterozygotes: a meta-analysisThorax, 2004
- American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin DeficiencyAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Cost-Effectiveness Analysis of Augmentation Therapy for Severe α1-Antitrypsin DeficiencyAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Augmentation Therapy With α1-AntitrypsinChest, 2003
- Worldwide Racial and Ethnic Distribution of α1-Antitrypsin DeficiencyChest, 2002
- Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in α1-Antitrypsin MZ Heterozygotes: A Longitudinal Study of the General PopulationAnnals of Internal Medicine, 2002
- Pharmacoeconomic Evaluation of COPDChest, 2000
- Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects.Journal of Clinical Investigation, 1981